Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin maintenance after first-line doxorubicin for advanced or metastatic soft tissue sarcoma
NL-OMON45391Phase 3Withdrawn
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jun 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in soft tissue sarcoma (STS) comparing Maintenance trabectedin with Observation (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2017; status: withdrawn.
02
Drugs
trabectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON45391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45391.